Skip to main content
. 2023 Jun 28;13(1):99. doi: 10.1038/s41408-023-00865-z

Fig. 3. TTD and OS by single-hit and multi-hit TP53 aberrations.

Fig. 3

In a subgroup of 496 patients (66.4% of the total population), TP53 aberrations in combination in 250 patients had no significant impact on TTD (a) and OS (b) as compared with TP53 deletion in 112 patients or TP53 mutations alone in 134 patients.